1. Scrip
  2. >>Business
  3. >>Deals

Zymergen Buy Will Enhance Ginkgo’s Services, Accelerate Growth

Deal Valued At $300m

 
• By Mandy Jackson

Troubled Zymergen will continue its ongoing restructuring efforts and Ginkgo, which has seen its own challenges since going public, will use Zymergen’s automation expertise to accelerate its growth.

The magnet attracts figures from the crowd. Talent acquisition concept.
Ginkgo will bring on Zymergen's automation experts but two other business units are being spun out • Source: Shutterstock

Two service providers with similar offerings for biopharmaceutical, industrial, cosmetic and agricultural clients – Ginkgo Bioworks and Zymergen, Inc. – will combine under one name as Ginkgo takes advantage of difficult financial market conditions to acquire Zymergen in an all-stock transaction.

Both companies use synthetic biology and other technologies to enable more efficient drug development and manufacturing, and provide similar services...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By Mandy Jackson

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.